Novartis, Multiple Sclerosis, MSToronto2026, Remibrutinib, REMODEL-1, REMODEL-2, Kesimpta, Ofatumumab, Pediatric MS, Relapsing Multiple Sclerosis, BTK Inhibitor, NEOS Study

Basel, Switzerland, October 7, 2026 Novartis is set to present an extensive body of new multiple sclerosis (MS) clinical...